Literature DB >> 17873136

Processing of generator-produced 68Ga for medical application.

Konstantin P Zhernosekov1, Dimitry V Filosofov, Richard P Baum, Peter Aschoff, Heiner Bihl, Anatoli A Razbash, Markus Jahn, Mark Jennewein, Frank Rösch.   

Abstract

UNLABELLED: The (68)Ge/(68)Ga generator provides an excellent source of positron-emitting (68)Ga. However, newly available "ionic" (68)Ge/(68)Ga radionuclide generators are not necessarily optimized for the synthesis of (68)Ga-labeled radiopharmaceuticals. The eluates have rather large volumes, a high concentration of H(+) (pH of 1), a breakthrough of (68)Ge, increasing with time or frequency of use, and impurities such as stable Zn(II) generated by the decay of (68)Ga, Ti(IV) as a constituent of the column material, and Fe(III) as a general impurity.
METHODS: We have developed an efficient route for the processing of generator-derived (68)Ga eluates, including the labeling and purification of biomolecules. Preconcentration and purification of the initial generator eluate are performed using a miniaturized column with organic cation-exchanger resin and hydrochloric acid/acetone eluent. The purified fraction was used for the labeling of nanomolar amounts of octreotide derivatives either in pure aqueous solution or in buffers.
RESULTS: Using the generator post-eluate processing system, >97% of the initially eluated (68)Ga activity was obtained within 4 min as a 0.4-mL volume of a hydrochloric acid/acetone fraction. The initial amount of (68)Ge(IV) was decreased by a factor of 10(4), whereas initial amounts of Zn(II), Ti(IV), and Fe(III) were reduced by factors of 10(5), 10(2), and 10, respectively. The processed (68)Ga fraction was directly transferred to solutions containing labeling precursors-for example, DOTA-dPhe(1)-Tyr(3)-octreotide (DOTATOC) (DOTA = 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid). Labeling yields of >95% were achieved within 10 min. Overall yields reached 70% at 20 min after generator elution relative to the eluted (68)Ga activity, not corrected for decay. Specific activities of (68)Ga-DOTATOC were 50 MBq/nmol using a standard protocol, reaching 450 MBq/nmol under optimized conditions.
CONCLUSION: Processing on a cation-exchanger in hydrochloric acid/acetone media represents an efficient strategy for the concentration and purification of generator-derived (68)Ga(III) eluates. The developed scheme guarantees high yields and safe preparation of injectable (68)Ga-labeled radiopharmaceuticals for routine application and is easy to automate. Thus, it is being successfully used in clinical environments and might contribute to a new direction for clinical PET, which could benefit significantly from the easy and safe availability of the radionuclide generator-derived metallic positron-emitter (68)Ga.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17873136     DOI: 10.2967/jnumed.107.040378

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  134 in total

1.  The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy.

Authors:  Jean-Mathieu Beauregard; Michael S Hofman; Grace Kong; Rodney J Hicks
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-09-20       Impact factor: 9.236

Review 2.  Feasibility and availability of ⁶⁸Ga-labelled peptides.

Authors:  Clemens Decristoforo; Roger D Pickett; Alfons Verbruggen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

Review 3.  ⁶⁸Ga-labelled peptides for diagnosis of gastroenteropancreatic NET.

Authors:  Valentina Ambrosini; Davide Campana; Paola Tomassetti; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

4.  68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with ¹¹¹In-DTPA-octreotide (OctreoScan®).

Authors:  Yodphat Krausz; Nanette Freedman; Rina Rubinstein; Efraim Lavie; Marina Orevi; Sagi Tshori; Asher Salmon; Benjamin Glaser; Roland Chisin; Eyal Mishani; David J Gross
Journal:  Mol Imaging Biol       Date:  2011-06       Impact factor: 3.488

Review 5.  Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease.

Authors:  Thaddeus J Wadas; Edward H Wong; Gary R Weisman; Carolyn J Anderson
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

6.  Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE.

Authors:  Irene Virgolini; Valentina Ambrosini; Jamshed B Bomanji; Richard P Baum; Stefano Fanti; Michael Gabriel; Nikolaos D Papathanasiou; Giovanna Pepe; Wim Oyen; Clemens De Cristoforo; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-10       Impact factor: 9.236

7.  Exploring new frontiers in molecular imaging: Emergence of Ga PET/CT.

Authors:  Eik Hock Tan; Soon Whatt Goh
Journal:  World J Radiol       Date:  2010-02-28

8.  Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours.

Authors:  Rakesh Kumar; Punit Sharma; Pramod Garg; Sellam Karunanithi; Niraj Naswa; Raju Sharma; Sanjay Thulkar; Sneh Lata; Arun Malhotra
Journal:  Eur Radiol       Date:  2011-07-13       Impact factor: 5.315

Review 9.  Labeling peptides with PET radiometals: Vulcan's forge.

Authors:  Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01       Impact factor: 9.236

10.  Repeatability of gallium-68 DOTATOC positron emission tomographic imaging in neuroendocrine tumors.

Authors:  Yusuf Menda; Laura L Boles Ponto; Michael K Schultz; Gideon K D Zamba; G Leonard Watkins; David L Bushnell; Mark T Madsen; John J Sunderland; Michael M Graham; Thomas M O'Dorisio; M Sue O'Dorisio
Journal:  Pancreas       Date:  2013-08       Impact factor: 3.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.